2026-05-31 23:00
Economic Observation Network The clinical data of the core pipeline pan RAS molecular gel ERAS-0015 is positive, and a clinical trial cooperation agreement has been reached with Merck.
Business Progress
The company announced that its core pipeline drug, pan RAS molecular gel ERAS-0015, has obtained positive preliminary data in phase 1 clinical trials. The data shows that the drug exhibits anti-tumor activity as a monotherapy in non-small cell lung cancer and pancreatic ductal adenocarcinoma patients with KRAS G12X mutation, and overall tolerability is good
The company announced a clinical trial cooperation and supply agreement with MSD to jointly evaluate the combination of ERAS-0015 and MSD for the anti-PD-1 therapy KEYTRUDA ® Pembrolizumab is used to treat solid tumors with RAS mutations
The above content is based on publicly available information and does not constitute investment advice.
In the live broadcast of the 2026 Haier Hope Primary School Children's Day Science and Technology Experience Day, Mei Feng, Chairman of the China Youth Foundation, praised Haier: cooperating with Haier for public welfare can be divided into three levels: public donation, resource linkage, and value co creation. Haier adheres to long termism and a sense of social responsibility, making public welfare projects more in-depth and effective.
CEO of Bangyao Biotechnology responds: has never been subject to regulatory interviews due to BD
Computing power leasing 'grabbing the beach' in 2026
WeChat registration or login
